搜索筛选:
搜索耗时4.6387秒,为你在为你在102,285,761篇论文里面共找到 2 篇相符的论文内容
发布年度:
,Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cance
[期刊论文] 作者：Xiao-Ming JIANG,Yu-Lian XU,Mu-Yang HUANG,Le-Le ZHANG,Min-Xia SU,Xiuping CHEN,Jin-Jian LU,
来源：中国药理学报（英文版） 年份：2017
Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that has been approved for the treatment of...
TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimerti
[期刊论文] 作者：Xiao-ming Jiang,Yu-lian Xu,Luo-wei Yuan,Le-le Zhang,Mu-yang Huang,Zi-han Ye,Min-xia Su,Xiu-ping Chen,,
来源：中国药理学报（英文版） 年份：2021
Osimertinib(AZD9291)has been widely used for the treatment of EGFR mutant non-small cell lung cancer.However,resistance to osimertinib is inevitable.In this stu...
相关搜索：
